TRANSGENE (EPA:TNG) | Finanzwire

Basculer en Français

11026	Companies
241675	Keywords
170144	Articles
130116	Press releases

Home
Companies
TRANSGENE

BRIEF

published on 11/25/2025 at 19:20, 9 months 24 days ago

Transgene Launches €105 Million Fundraising Initiative

Biotechnology Investment Transgene Fundraising Myvac® Program Cancer Vaccine Development Institutional And Retail Offerings
PRESS RELEASE

published on 11/25/2025 at 19:15, 9 months 24 days ago

Transgene launches a fundraising campaign for approximately 105 million euros
Transgene launches a fundraising of approximately 105 million euros through new share issuance to investors. Funding to advance myvac program for personalized cancer vaccines and ensure financial stability until early 2028

Fundraising Financial Stability Cancer Vaccines Transgene Myvac Program
BRIEF

published on 11/06/2025 at 08:35, 10 months 13 days ago

Transgene to Present VacDesignR® Tool at ESMO AI 2025

Transgene VacDesignR® INTV ESMO AI 2025 HPV-negative Cancer
PRESS RELEASE

published on 11/06/2025 at 08:30, 10 months 13 days ago

Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines
Transgene to present VacDesignR® tool at ESMO-AI 2025 for optimized cancer vaccine design. Tool enhances virus efficiency and yield for individualized therapies

Cancer Vaccines Computational Tool Transgene VacDesignR ESMO-AI 2025
BRIEF

published on 11/04/2025 at 17:55, 10 months 15 days ago

Transgene presents its progress and financial situation as of Q3 2025

Funding Immunotherapy Transgene TG4050 SITC 2025
PRESS RELEASE

published on 11/04/2025 at 17:50, 10 months 15 days ago

Transgene Provides Business and Financial Update for Q3 2025
Transgene provides business and financial update for Q3 2025, including immunogenicity data of INTV TG4050 in Phase I study on HNSCC. Company focuses on cancer immunotherapies

Financial Update Transgene INTV TG4050 Cancer Immunotherapies HNSCC
BRIEF

published on 10/20/2025 at 08:35, 10 months 30 days ago

Transgene and BioInvent's BT-001 Shows Promising Antitumor Activity

Cancer Immunotherapy Transgene Oncolytic Virus BT-001 Antitumoral Activity
PRESS RELEASE

published on 10/20/2025 at 08:30, 10 months 30 days ago

Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
Transgene and BioInvent's BT-001 oncolytic virus in combination with pembrolizumab shows positive antitumoral activity in refractory tumors. Exciting clinical data presented at ESMO 2025

Transgene Oncolytic Virus BioInvent BT-001 Pembrolizumab
BRIEF

published on 06/13/2025 at 08:35, 1 year 3 months ago

Transgene Engages with Key Biotech Industry Platforms

Cancer Treatment Clinical Data Immunotherapy Transgene Biotech Meetings
PRESS RELEASE

published on 06/13/2025 at 08:30, 1 year 3 months ago

Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
Transgene to participate in upcoming meetings with biotech industry leaders to discuss positive clinical data on neoantigen cancer vaccine TG4050 and present innovative immunotherapies. Learn more at www.transgene.com

Biotech Industry Clinical Data Transgene Immunothérapies Neoantigen Cancer Vaccine

Accesswire

Published on 09/19/2026 at 00:55, 23 hours 36 minutes ago

Gossan Resources Announces Changes to Board and Management
Published on 09/18/2026 at 23:50, 1 day ago

Mako Mining Announces Equity Incentive Grants
Published on 09/18/2026 at 22:00, 1 day 2 hours ago

Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 1 day 3 hours ago

Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 1 day 10 hours ago

AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement

View all ACCESSWIRE

EQS Group

Published on 09/19/2026 at 16:40, 7 hours 51 minutes ago

2026 Cross-Strait (Kunshan) Mid-Autumn Lantern Festival Opens
Published on 09/19/2026 at 13:15, 11 hours 16 minutes ago

Eurobattery Minerals AB has received information regarding court judgment and criminal suspicion concerning the CEO
Published on 09/19/2026 at 07:30, 17 hours 1 minute ago

Hong Kong sets out initiatives to secure long-term development of pillar industries
Published on 09/18/2026 at 18:45, 1 day 5 hours ago

Holding(s) in Company
Published on 09/18/2026 at 18:44, 1 day 5 hours ago

EQS-Adhoc: Enapter AG announces preliminary, unaudited figures for the first half of 2026 and restructures its US sales operations – one-off expense of EUR 17 million

Les Echos

Published on 09/18/2026 at 18:34, 1 day 5 hours ago

Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/18/2026 at 17:45, 1 day 6 hours ago

Press Release_Carrefour Bond_September 2026
Published on 09/18/2026 at 17:45, 1 day 6 hours ago

Share buyback for cancellation
Published on 09/17/2026 at 17:40, 2 days 6 hours ago

Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 20:46, 3 days 3 hours ago

LNA SANTE : 2026 First Half Results

View all LES ECHOS COMFI WIRE